Atorvo+™
Atorvo+ Development
Atorvo+™ represents the first product emerging from Indication Bioscience’s Statin+™ platform, a next-generation therapeutic approach designed to enhance cardiovascular outcomes through rational combination science.
Atorvo+™ combines atorvastatin, the active component of Lipitor®—the world’s most successful cholesterol-lowering therapy—with a proprietary, FDA-approved small molecule in a fixed-dose formulation. This novel combination is being developed to address the tolerability and adherence challenges that limit the long-term effectiveness of standard statin therapy.
The Phase I pharmacokinetic (PK) study for Atorvo+™ was successfully completed in 2025, providing the foundation for further development. Topline results are expected in Fall 2025, with a Phase II program now in planning in collaboration with leading global development partners.
Atorvo+™ is the first in a pipeline of differentiated fixed-dose combinations being advanced under the Statin+™ platform, which is designed to extend across other major statins, including rosuvastatin, simvastatin, and lovastatin.
- 1. JAMA Network Open. 2021;4(11):e2135371. doi:10.1001/jamanetworkopen.2021.35371
Pre-Clinical
At Indication Bioscience, our pre-clinical research lays the foundation for transformative therapies. By combining rigorous scientific methods with innovative technologies, we evaluate the safety, efficacy, and unique advantages of our drug candidates before advancing to clinical trials. Our lead program, Atorvo+, has demonstrated compelling pre-clinical data, showcasing its potential to address statin intolerance while maintaining effective cholesterol management. These findings reinforce our commitment to advancing therapies that solve real-world challenges and improve patient outcomes.
Accelerated Pathway
At Indication Bioscience, we are pursuing an accelerated development strategy to bring innovative cardiovascular therapies to patients more efficiently.
By leveraging the existing safety and efficacy data of well-characterized compounds, our approach reduces the time and cost typically associated with early-stage drug development—without compromising scientific or regulatory rigor.
This streamlined model enables us to focus on addressing critical unmet needs in cardiovascular care, such as improving statin tolerability and long-term adherence, while advancing high-quality programs like Atorvo+™ toward clinical proof of concept with greater speed and precision.